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INTERAKSI ANTARA SEL-SEL TUNJANG JANTUNG MENCIT DAN SEL-
SEL TUNJANG MESENKIMA UNTUK PROSES DIFERENSIASI SEL 
KARDIOMIOSIT IN VITRO 
 
ABSTRAK 
 
Latar Belakang: Sel-sel tunjang mesenkima (MSCs) terbukti dalam 
membantu proses pembaikan jantung melalui pengaktifan sel-sel jantung (CSCs) 
berikutan infaksi, tetapi pengeksploitasian secara in vitro melibatkan sinergi antara 
dua sel sebelum pemindahan sel masih kurang diketahui. Objektif: Kajian ini 
bertujuan untuk mengkaji kesan sinergi MSCs kepada diferensiasi sel kardiomiosit. 
Kaedah: CSCs yang mengekspres c-kit dan MSCs tulang diperoleh daripada mencit 
C57BL/6N (n=9). Diferensiasi CSCs diuji selepas diasingkan daripada MSCs 
berikutan ko-kultur dengan menggunakan zarah oksida besi bersaiz micron, dan 
dibandingkan dengan CSCs yang dirawat dengan medium terkondisi MSCs atau 
tanpa sebarang rawatan. Diferensiasi kardiomiosit dikesan menggunakan 
penwarnaan imunofluorescein dan diukur menggunakan tindakbalas polimerase 
berantai secara quantitatif. Semua data dianalis dengan ANOVA sehala. Keputusan: 
Lebih daripada 80% CSCs yang berkecambah daripada satu sel berada pada fasa G1, 
dengan masa penduaan populasi sebanyak 17.2 ± 0.2 jam. Populasi CSC Sox2
positif
 
GATA4
malap 
Nkx2.5
malap 
yang diinduksi dengan deksametason menunjukkan 
diferensiasi kardiomiosit yang lebih tinggi berbanding populasi Sox2
negatif 
GATA4
tinggi 
Nkx2.5
tinggi
 selepas diko-kultur dengan MSCs. Hal ini terbukti dengan 
ekpresi yang lebih tinggi untuk cTnI, Mef2c dan GATA4 (p<0.001). Kesan ini 
adalah lebih besar berbanding dengan CSCs yang dirawat dengan medium terkondisi 
xii 
 
MSCs. Akan tetapi, kesan sinergi untuk diferensiasi kardiomiosit selepas ko-kultur 
tidak ditunjukkan dalam populasi Sox2
negatif
 GATA4
tinggi 
Nkx2.5
tinggi
 CSCs. Walau 
bagaimanapun, tiada perbezaan dalam pembentukan kardiomiosit di bawah 
diferensiasi yang bergantung kepada factor tumbesaran. Hal ini terbukti dengan 
ekpresi cTnI dan α-SA. Kesimpulan: Interaksi CSCs dan MSCs secara langsung 
diperlukan untuk sinergi diferensiasi kardiomiosit secara in vitro, tetapi manfaat ini 
adalah terhad kepada Sox2
positif
 GATA4
malap 
Nkx2.5
malap
 populasi. Tesis ini 
mentafsirkan sinergi antara MSCs dan CSCs, dan menyokong penggunaan kedua-
dua sel dalam terapi klinikal.  
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INTERACTION BETWEEN MURINE CARDIAC STEM CELLS AND BONE 
MARROW-DERIVED MESENCHYMAL STEM CELLS FOR 
CARDIOMYOCYTE DIFFERENTIATION IN VITRO 
 
ABSTRACT 
 
Background: Bone marrow-derived mesenchymal stem cells (MSCs) has 
been shown to facilitate heart repair via activation of endogenous cardiac stem cells 
(CSCs) following infarction, but little is known if the synergy of the two cells can be 
exploited in vitro prior to transplantation. Objective: This study aimed to examine the 
synergistic effects of MSCs on CSC cardiomyocyte differentiation. Methods: C-kit 
CSCs and MSCs were isolated from 4-6 weeks C57BL/6N mice (n=9). CSC 
cardiomyocyte differentiation was tested after re-isolated from MSC co-culture using 
micron-sized particles of iron oxide, and compared to CSCs treated with MSC-
conditioned medium (CdM) or without any treatment. Cardiomyocyte differentiation 
was detected using immunofluorescence staining and quantified using qPCR. All 
data were analysed by one way ANOVA. Results: More than 80% clonogenic 
amplified, colony-forming c-kit CSCs were at G1 phase, with a population doubling 
time of 17.2 ± 0.2 hr. Sox2
pos 
GATA4
dim 
Nkx2.5
dim 
CSCs, when induced by 
dexamethasone, showed greater cardiomyocyte differentiation than the Sox2
neg 
GATA4
high 
Nkx2.5
high
 CSCs after co-cultured with MSCs, as evidenced by higher 
cTnI, Mef2c and GATA4 expression (p<0.001). This effect was greater than CSCs 
treated with CdM. However, direct MSC contact did not show synergistic effects on 
the cardiomyocyte differentiation of Sox2
neg 
GATA4
high 
Nkx2.5
high
 CSCs. 
Nevertheless, there was no difference in cardiomyocyte formation under growth 
xiv 
 
factor directed differentiation, as evidenced by the presence of cardiac troponin I and 
α- sacromeric actin. Conclusion: Direct MSC-CSC interaction is needed to synergise 
CSC cardiomyocyte differentiation in vitro, but the benefit is confined to Sox2
pos 
GATA4
dim 
Nkx2.5
dim
 CSCs only. This thesis defines the synergistic interactions 
between MSCs and CSCs, and support the use of two cells in combination for 
clinical therapy.  
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1.0 INTRODUCTION 
1.1  Cardiovascular Disease  
Cardiovascular disease (CVD) remains the number one, non-communicable killer 
disease which recorded a mortality rate that reached 17.5 million in 2012 and 
accounted for 46.2% of all reported death around the globe in 2014 (Figure 1.1) [1]. 
In Malaysia, CVD was associated with 25.4% of all death in government hospital in 
2010 [2]. This is further complicated by 43% surge in hypertension, 88% diabetes 
and 250% obesity in Malaysia population from year 1996 to 2006 [2], the three most 
common risk factors that are highly associated with acute coronary syndrome (ACS) 
[3]. According to Malaysian National Cardiovascular Disease Database-Acute 
Coronary Syndrome Registry, incidence of unstable angina (UA), non-ST elevation 
myocardial infarction (NSTEMI) and ST elevation myocardial infarction (STEMI) as 
a result of ACS accounted for 3778, 4958 and 8130 cases respectively in 2006-2010 
[4]. For STEMI alone, the severe form of myocardial infarction that required 
immediate attention, the incidence increased by 200 cases in only 12 months [4]. 
With an average cost of $2000 (USD) for the treatment of one patient for an average 
length of stay in the hospital up to 9.2 days [5], this disease is undoubtedly imposing 
huge economic burden to the country.  
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Figure 1.1: Statistics of global mortality associated with different type of non-
communicable diseases in 2012 (adapted from WHO, 2014) 
 
1.2 Myocardial Infarction and Heart Failure Pathophysiology 
Myocardial infarction (MI) is a common cause of heart failure (HF). Approximately 
25% of myocardial infarcted patients will develop HF, as a result of severe 
dysfunction of the left ventricle and progressive heart remodelling post infarction [6]. 
MI is due to occlusion of the main coronary artery following ruptured atherosclerotic 
plague and thrombosis, which diminishes the delivery of oxygen and nutrient supply 
to the myocardium where the vessel serves [7]. Prolonged ischemia will eventually 
lead to irreversible cardiomyocyte necrosis and apoptosis, followed by fibrosis and 
scar formation, which interrupts the contractility of the ventricular muscles [7-9]. As 
a compensative mechanism to maintain cardiac output in response to acute myocyte 
loss, the remaining cardiomyocytes undergo hypertrophy [9] as a result of increased 
workload [10]. If it is left untreated, the infarcted heart will eventually remodel and 
the alteration of the architecture will continue to weaken the cardiac contractility, and 
subsequently render the heart to fail.  
46% 
22% 
11% 
4% 
17% 
Cardiovascular Disease
Cancer
Respiratory Disease
Diabetes
Others
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1.3 Current Treatment for Myocardial Infarction and Heart Failure 
The primary intervention for infarcted myocardium is to restore blood flow to the 
affected heart muscles. Patients with unstable angina and non ST elevated 
myocardial infarction (NSTEMI) are usually given drugs such as aspirin, 
clopidogrel, β-blocker, statins and angiotensin converting enzyme (ACE) inhibitor as 
primary management [11]. However, with the more serious ST elevated myocardial 
infarction (STEMI), reperfusion may be achieved with coronary artery bypass 
grafting (CABG) or insertion of stents in the blocked artery [3]. Although these 
approaches can alleviate the symptoms and improve patients’ quality-of-life, the 
benefit is short-term as they do not replace the loss myocardium with new functional 
cardiomyocytes [12]. 
Currently, heart transplantation is the only treatment for end stage HF. However, this 
procedure is invasive and possesses high risk of infection and organ rejection [13-
15]. Furthermore, donor heart is not readily available, making it an unfavourable 
option to most patients [13-15]. Recently, Ott and colleagues demonstrated a concept 
of producing bio-engineered heart by using the natural heart from rat [16]. The heart 
scaffold is de-cellularised using detergents, then re-cellularised by introducing 
neonatal cardiac cells and endothelial cells [16]. The bio-engineered heart started to 
beat after 8 days in a bioreactor that supplies electrical stimulus. However, the 
cardiac output was only 2% when compared to the normal adult heart [16].  
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1.4 Regeneration of Adult Heart using Cardiomyocyte 
The rate of myocyte turnover in human was found to be very low, with annual rate of 
less than 1%, and the rate is inversely proportional to age [17, 18]. This explains why 
the heart is unable to regenerate by itself following ischemic insults. Studies showed 
that transplantation of neonatal cardiomyocytes engrafted and coupled with the pre-
existing cardiomyocytes [19] and regenerated the heart [20, 21]. However, the source 
of human neonatal cardiomyocytes remains an unsolved problem to enable clinical 
transplantation.  
1.5 Stem Cells  
Stem cells are a group of primitive cells which are capable of self-renewal, 
proliferate and differentiate into cells with specialised function, such as 
cardiomyocytes [22, 23]. Stem cells are generally categorised into three groups, the 
embryonic stem cells, induced-pluripotent stem cells and adult stem cells.  
1.5.1   Embryonic Stem Cells  
Embryonic stem cells (ESCs) are pluripotent cells originated from inner cell mass of 
blastocyte, with the ability to form all cells in human body except the extra-
embryonic tissues [24]. The potency of ESCs make them a promising cell source to 
generate new cardiomyocytes, but at the same time possess the possibility of tumour 
formation [25, 26]. Although tumorigenesis can be prevented by using cardiac 
lineage committed ESCs by differentiating them in vitro before transplantation [27-
30], only 5-20% of the total embryoid body were shown to successfully 
differentiated into cardiomyocytes [31]. Laflamme and colleagues rectified the low 
differentiation problem by creating a highly purified cardiomyocyte population by 
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treating ESCs with activin A and bone morphogenic protein 4 to prolong the survival 
and engraftment after transplantation [27]. Nonetheless, the use of human ESCs has 
been associated with huge ethical controversy as the procedures involve sacrifice of 
embryos [32-34]. In addition, the allogenicity of ESCs may subject recipient patients 
to long term immunosuppression in order to minimise rejection [32, 35]. 
1.5.2   Induced Pluripotent Stem Cells 
Induced pluripotent stem cells (iPSCs) are generated by reprogramming adult 
fibroblasts through ectopic expression of four pluripotency-associated transcription 
factors, namely the OCT3/4, Sox-2, c-Myc and Klf4 [36]. The generated iPSCs have 
similar characteristics like ESCs. As the cells can be derived from autologous skin 
fibroblast, the technology offers a novel source of pluripotent stem cells to generate 
cardiomyocytes with minimal concerns of immune rejection and ethical issues [37]. 
IPSCs can be differentiated into myocytes via the formation of embryoid bodies [38, 
39] with exhibit spontaneous contraction when plated on gelatin-coated flask [38, 
39]. Even though previous study [40] showed that iPSCs have the potential to 
regenerate the heart in vitro, the safety and feasibility of using these iPSCs in vivo 
and in early clinical trials remain a question due to possible aberrant changes in the 
epigenomic of the fibroblast during the reprogramming process [41].  
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1.5.3 Adult Stem Cells  
1.5.3.1 Skeletal Myoblasts 
Skeletal myoblasts are satellite cells which maintain the cellular turnover of skeletal 
muscles [42]. Autologous skeletal myoblasts which can be isolated from patients are 
multipotent and have minimal risk of tumour formation compared to pluripotent stem 
cells due to their restricted lineage [42]. These cells were among the first cell 
candidates used in clinical trials for cardiac therapy [24]. Several in vivo studies, as 
demonstrated in small and big animals such as mouse [43] , rat [44, 45], sheep [46, 
47], rabbit [48, 49] and pig [50, 51] showed that these skeletal myoblasts are capable 
of regenerating the infarcted myocardium, by slowing the progression of heart 
remodelling and alleviating the left ventricular functions [52]. These data prompted 
the phase I clinical trials to access the safety and feasibility of using skeletal 
myoblasts in human [53-56]. The administration of skeletal myoblasts was found to 
be safe and feasible in phase I trials, and Menasche and colleagues continue with the 
Phase II MAGIC trials. 
Table 1.1: Skeletal myoblast phase I clinical trials 
Number of 
Patients 
Changes in left ventricular ejection fraction Reference 
5 36 ± 11% - 41 ± 9% (3 months) 
36 ± 11% - 45 ± 8% 
[53] 
10 29% - 47% [54] 
30 28% -36% [55] 
12 Control: 33.6 ± 9.3% - 38.6 ± 11% 
Treated: 35.5 ± 2.3 - 55.1 ± 8.2 
[56] 
 
However, the Phase II trial outcome was disappointing as restoration of left 
ventricular ejection fraction (p = 0.62) was not observed regardless of the number of 
injected skeletal myoblasts [57]. Although patients that received high dose of skeletal 
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myoblasts showed a significant decrease in left ventricular volume as compared to 
the placebo group [57], the major drawback is the high incidence of arrhythmias after 
skeletal myoblasts administration, with 12% of patients having arrhythmia episodes 
in the low dosage group and 17% in the high dosage group. The observation was 
attributed to the absence of gap junction connexin-43 which causes the administered 
skeletal myoblasts to contract independently from the pre-existing cardiomyocytes in 
the heart [58].  
1.5.3.2 Bone Marrow-derived Stem Cells 
Bone marrow mononuclear cells (BM-MNCs) are isolated via bone marrow 
aspiration which consist of a mixed population of regenerative and non-regenerative 
cells [59]. Most clinical trials using BM-MNCs as cell candidate for heart therapy 
showed inconsistent results (Table 1.2). Meta-analyses revealed that the benefits 
from BM-MNCs are modest [60-62]. Some claimed that the disappointing outcome 
from the trials may be a result of variation in the transplantation protocols, such as 
the number of administered cells and the route of administration [59]. Nevertheless, a 
recent study by Loffredo and colleagues re-defined the role of BM-MNCs in heart 
regeneration, evident by in vivo activation of endogenous c-kit cardiac stem cells 
following the administration of lin
neg 
c-kit
pos
 BM-MNCs into the infarcted mouse 
heart [63]. In other words, BM-MNCs act through paracrine effects.  
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Table 1.2: List of clinical trials using bone marrow mononuclear cells 
Study Number of 
Patients 
Dose Effects on Ejection 
Fraction 
References 
Trials in MI  
TOPCARE-
AMI (2002) 
20 7.3 X 10
6
 + 16% [64] 
BOOST (2004) 60 2.4 X 10
9
 + 6.7% [65] 
BOOST# 
(2006) 
60  Neutral* [66] 
REPAIR 
(2006) 
204 1.98 X 10
8
 + 5% [67] 
Leuven 
(2006) 
67 4.8 X 10
8
 Neutral* [68] 
ASTAMI 
(2006) 
97 6.8 X 10
7
 Neutral* [69] 
TCT-STAMI 
(2006) 
20 4 X 10
7
 + 10% [70] 
FINCELL 
(2008) 
80 3.6 X 10
9
 + 7.1% [71] 
HEBE  
(2008) 
200 2.96 X 10
8
 + 2% [72] 
ASTAMI# 
(2009) 
97 6.8 X 10
7
 Neutral* [73] 
REGENT 
(2009) 
200 1.90 x 10
6
 + 3% [74] 
BONAMI 
(2010) 
101 1 X 10
8
 Neutral* [75] 
HEBE# 
(2011) 
200 2.96 X 10
8
 + 4% [76] 
Late-TIME 
(2011) 
87 1.5 X 10
8
 Neutral* [77] 
TIME (2012) 120 1.5 X 10
8
 Neutral* [78] 
Trials in Congestive Heart Failure  
TOPCARE-
CHD (2006) 
92 2.1 X 10
8
 + 2.9% [79] 
FOCUS-
CCTRN 
(2012) 
92 1 X 10
8
 Neutral* [80] 
# follow-up studies  
* p>0.05 compared to placebo group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9 
 
1.5.3.3 Bone Marrow-derived Mesenchymal Stem Cells  
The Mesenchymal and Tissue Stem Cell Committee of the International Society for 
Cellular Therapy (ISCT) defines mesenchymal stem cells (MSCs) as cells with 
plastic adherence characteristic when maintained in standard culture condition,  
expressed CD 105, CD73 and CD 90 but not CD 34, CD 45, CD 14 or CD 11b, CD 
79α or CD 19, and HLA-DR and possess the ability to form adipocytes, 
chondrocytes and osteoblasts in vitro [81]. These cells are also known to be immune-
privileged due to low expression of MHC Class I and lack of MHC Class II [82, 83], 
which makes the cells suitable for allogeneic transplantation [83]. In contrast, Schu’s 
group claimed that MSCs are not entirely immune-privileged [83]. MSCs treated 
with pro-inflammatory cytokines IFN-γ and IL-1β upregulated both MHC I and 
MHC II, causing around 39% of MSC lysis by T cells [83]. In addition, in vivo 
results showed that the survival of allogeneic MSCs was lower compared to 
syngeneic MSCs [83].  
Several plausible regeneration mechanisms involving MSCs have been proposed, 
such as transdifferentiation into cardiomyocytes [84, 85], secretion of 
cardioprotective and cardiorestorative paracrine factors [86, 87] and activation and 
homing of cardiac stem cells to the infarct zone [88]. Transdifferentiation of MSCs 
into cardiac lineage can be achieved by inducing the cells with chemical such as 5-
azacytidine [89-91], but the frequencies of cardiomyocytes formation from MSCs 
were found to be low [92]. Other studies also showed that although 
transdifferentiated MSC expressed cardiac specific markers, α-actinin and cardiac 
troponin T when co-cultured with rat or mouse myocytes in vitro [93, 94], the 
electrophysiological analysis revealed that the cells did not possess the similar 
electrical properties like a functional cardiomyocytes [95]. Nonetheless, several in 
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vivo studies showed MSCs improve myocardial performance even with low rate of 
engraftment and differentiation [96, 97], and the benefit was mainly attributed to its 
paracrine signalling. 
MSCs are known to secrete a wide range of cardioprotective cytokines, growth 
factors and chemokines [98] such as IL-6, IL-8, TIMP-2, VEGF, MCP-1, SDF-1, 
bFGF and angiopoietin-1 [87, 99-101]. These factors have also been shown to 
involve in neovascularisation [102, 103] which protect further functional 
deterioration of the infarcted heart [104], prevent scar formation [105] and enhance 
proliferation, survival, recruitment and homing of  cardiac stem cells to the injured 
site [87, 88]. More recently, exosomes that were found in MSC conditioned medium 
through HPLC fractionation [106, 107] have shown to exert pro-survival effects on 
the surviving cardiomyocytes in the infarcted heart via the activation of P13K/Akt 
pathway, and attenuate heart remodelling and restore cardiac functions post 
administration [107].  
Three high profile clinical trials, the POSEIDON [108], the PROMETHEUS [109] 
and the MSC-HF [110] trials were initiated to test the safety, feasibility and efficacy 
of MSC therapy in injured myocardium. In POSEIDON, both allogeneic and 
autologous BM-MSCs in treating patients with ischemic cardiomyopathy were found 
safe with no observed adverse effects following the therapy [108]. PROMETHEUS 
and MSC-HF administered autologous BM-MSCs to patients underwent coronary 
artery bypass grafting [109] and chronic ischemic heart failure [110], respectively. 
All these trials showed promising improvement in overall global functions after MSC 
administration.  
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1.6 Cardiac-derived Stem Cells 
 
 
The heart was once thought to be a terminally differentiated organ and the paradigm 
was used for decades until it was challenged by the discovery of cardiac-derived 
stem cells (CSCs) [22]. The endogenous CSCs were found to be multipotent, self-
renewing and capable of forming cardiomyocytes, smooth muscle cells and 
endothelial cells [22, 23]. These primitive cells are thought to be responsible for 
cardiac cellular homeostasis in the heart [111]. Several types of CSCs have been 
identified and isolated based on their surface marker and in vitro characteristics, 
namely the c-kit [22, 112], Sca-1 [113, 114], Isl-1 [115, 116], cardiac side population 
[117, 118], cardiospheres [23] and cardiosphere-derived cells [119, 120].  
1.6.1 C-kit
pos
 Cardiac Stem Cells 
The first reported primitive CSCs present in the heart were isolated based on the 
expression of stem cell factor receptor CD 117, or c-kit. These cells do not express 
CD 34 and CD45 [22, 23, 121]. C-kit
pos
 CSCs were also shown to play an important 
role in cardiomyogenesis in embryonic and neonatal heart development [122]. In 
adult heart, most of these cells were found to reside in the atrium and the ventricular 
apex, albeit at a very low density (1 cell in every 10,000 myocytes) [22]. Owing to 
the scarcity of the cells, optimised protocol has been developed to isolate and expand 
these cells, which can be maintained up to 40 passages in vitro without affecting the 
stemness and characteristics [123].  
Pre-clinical studies showed that these c-kit
pos
 CSCs can regenerate both the rat [22, 
112, 124] and mice [23, 125] hearts post infarction via the formation of new 
myocytes and vasculatures, and protect the pre-existing cardiomyocytes from 
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apoptosis through IGF-1 secretion [126, 127]. An elegant experiment by Ellison and 
colleagues revealed the significant role of c-kit CSCs in endogenous heart repair 
through total ablation of proliferating cells in the heart by 5-flurouracil 
administration into isoproterenol-induced infarcted mice  [112]. The absence of 
proliferative cells blunted the recovery of the injured heart and the effect could then 
be reversed through administration of c-kit
pos 
CSCs, evident by new myocyte 
formation [112]. 
Phase I clinical trial, the Stem Cell Infusion in Patients with Ischemic 
cardiomyopathy trial, or SCIPIO, was initiated to treat patients with ischemic 
cardiomyopathy with c-kit
pos
 CSCs [128, 129]. The trial showed that c-kit
pos
 CSCs (1 
million) injection increased left ventricular ejection fraction and decreased scar 
tissues after 4 and 12 months of administration, with no reported adverse effects 
[128, 129]. The safety concern in regard to c-kit
pos
 CSC megadose was addressed by 
administering 20 million cells into swine heart [130], which showed neither 
detrimental effects on renal and liver functions, nor resulted in myocardial injury or 
impairment of left ventricle function [130].  
1.6.2 Sca-1
pos
 Cardiac Stem Cells 
Stem cell antigen-1 (Sca-1) belongs to the lymphocyte activation protein-6 (Ly6) 
gene family and was previously used in isolating hematopoietic stem cells [131]. 
Sca-1
pos 
CSCs were first identified in adult mouse heart by Oh and colleagues [113] 
and expressed the cardiac transcription factors, GATA-4, Mef2c and TEF-1 but not 
the hematopoietic markers (CD 45, CD 34, c-kit, Lmo2, GATA-2, and Tal/Scl2 
protein) and the endothelial markers (CD34, Flk1 and Flt-1) [113]. In human, the 
Sca-1-like CSCs was found mostly in the atrium, including the intra-atrium septal as 
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well as the atrium-ventricular boundary [114]. In vitro studies showed that these Sca-
1 expressing CSCs were capable of differentiating into beating clusters with 5-
azacytydine [113] or oxytocin [132] treatment and expressed both the cardiac 
transcription factors, GATA-4 and Nkx 2.5 [114, 132, 133] and the structural 
proteins such as α-sacromeric actin, cardiac troponin I, cardiac troponin T and 
myosin heavy chain [113, 132]. Transplantation of Sca-1
pos
 CSCs was shown to 
attenuate heart remodelling in vivo [134]. In addition to the observed increase in left 
ventricular ejection fraction post administration, Sca-1
pos
 CSC also induced 
vascularization in the peri-infarct zone [134]. The regenerative function of Sca-1
pos
 
CSCs is likely due to the secretion of SDF-1, which was shown to provide 
cardioprotective effects by preserving the infarcted heart and promote cell surviving 
through the STAT3 signalling pathway [135, 136].  
1.6.3 Isl-1
pos
 Cardiac Progenitor Cells 
The LIM-homeodomain transcription factors Isl-1 expressing cardiac progenitor 
cells, or cardioblasts were first described by Laugwitz and colleagues in rat, mouse 
and human heart [115]. Isl-1
pos
 CSCs were found abundantly in neonatal heart and 
are involved in cardiogenesis [137]. These cells express GATA-4 and Nkx2.5, but 
not Sca-1 or c-kit [115, 138] and have shown to developmentally contribute to the 
growth of the secondary heart field which include the right ventricles and the outflow 
tract [115, 138]. The embryonic stem cell-derived Isl-1
pos
 progenitor cells are capable 
of forming cardiomyocytes, smooth muscle cells and vascular endothelial cells and 
the mechanisms are largely controlled by the Wnt/β-catenin pathway [116, 139]. 
However, the number of these Isl-1
pos
 cells in the heart after birth is extremely low, 
with only 500-600 cells detected in 1-5 day old postnatal rat [115]. 
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1.6.4 Cardiac Side Population Cells 
Cardiac side population (SP) cells were identified based on its ability to efflux DNA 
binding dye Hoechst 33342 by the ATP-binding cassette transporter (ABCG2) [117, 
118]. These transporters enable the cells to excrete cytotoxic products, protect them 
from apoptosis [140], enhance its proliferation and inhibit myogenic differentiation 
in vitro [141]. Approximately 0.03% to 3.5% of SP cells can be isolated from adult 
heart using FACS sorting [117, 142-144]. When co-cultured with cardiomyocytes, 
more than 30% of these SP cells were shown to differentiate into mature 
cardiomyocytes [143, 145]. In addition, these SP cells were also able to differentiate 
into endothelial lineage when treated with vascular endothelial growth factor 
(VEGF) for 28 days [146].  
1.6.5 Cardiospheres and Cardiosphere-derived Cells 
Cardiospheres are 20-150 μm spheres generated from explant outgrowth from heart 
biopsies [23, 119]. These cardiospheres consist of  stem/progenitor cells which reside 
in the core and cardiac lineage committed cells and differentiated cells which 
comprise the outer layer of the spheres [23]. The three dimensional 
microenvironment of cardiospheres was shown to protect the c-kit
pos
 CSCs from 
oxidative stress as well as maintain its stemness and functions [147]. When these 
cardiospheres were expanded on fibronectin, the cardiosphere-derived cells (CDCs) 
become highly proliferative in monolayer, and are multipotent and clonogenic [148]. 
This enables fast expansion of the cells for heart therapy, with retained regenerative 
potentials [119, 120, 149]. The CDCs are heterogeneous and expressed stem cell 
markers; c-kit, Oct 3/4, Sox-2 and Klf4 as well as the mesenchymal markers; CD 90 
and CD 105 [120]. The therapeutic effects of CDCs have also been demonstrated in 
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many in vivo studies, ranging from small to big animals [149-151] and in human 
trials [152, 153]. These CDCs showed potentials in reducing infarct size, improving 
left ventricular ejection fraction and cardiac hemodynamic in infarcted animal 
models [149, 150] and the benefits could be maintained up to 16 weeks [120]. The 
positive observation in in vivo studies led to the initiation of randomised phase I 
clinical trial, the CArdiosphere-Derived aUtologous stem Cells to rEverse 
ventricUlar dySfunction study, or the CADUCEUS trial conducted in the United 
States [152]. However, no difference in left ventricular ejection fraction and end 
systolic/diastolic volume were observed with CDC administration despite significant 
reduction in scar mass [152].  
1.7 Cell Therapy with Combination of Different Stem Cells in Single 
Administration 
Most of the in vivo pre-clinical testing and clinical trials employ only single type of 
stem cells to examine its therapeutic efficacy in regenerating damaged myocardium. 
Regardless of the types, the density of CSCs in the adult heart is generally low [22, 
115, 117]. Thus, extensive expansion is required to scale up the cell number for 
therapy, which can also be time consuming.  To reduce the time period for cell 
expansion, combining different types of stem cells may serve as an alternate solution. 
The idea of combining two different types of stem cells stemmed from a report by 
Winter and colleagues, who showed better cardiac performance with greater 
amelioration of ejection fraction deterioration in animals when epicardium-derived 
cells were co-cultured and co-transplanted with Sca-1 cardiac progenitor cells [154]. 
Similarly, combination of  cardiac stem cells and circulatory angiogenic cells also 
showed superior global improvement compared to subjects that received single cells 
[155]. This concept prompted an in vivo study by Williams and colleagues to use 
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candidates which have been brought to clinical testing, the human c-kit
pos 
cardiac 
stem cells and bone marrow mesenchymal stem cells [156]. The study showed that 
the regenerative effects following co-administration of both MSCs and CSCs were 
greater compared to single cell-treated groups [156]. This excitement prompted 
series of experiments described in this thesis to decipher the synergy between 
mesenchymal stem cells and the c-kit expressing CSCs and exploit the interactions 
during CSC expansion in vitro.  
1.8 Magnetic Re-Isolation of Iron-Labelled Cells from Mixed Cell Culture: 
The Novel Use of Micron-Sized Iron Oxide Particle  
Micron-sized iron oxide particles (MPIO) are fluorescent microspheres made of 
polystyrene-divinyl benzene polymer with a magnetic core [157] which were widely 
used as a contrast agent for in vivo cellular tracking using magnetic resonance 
imaging (MRI) [120, 158, 159]. Due to its non-toxic, biologically inert 
characteristics, MPIO can easily be incorporated into multiple cell lines and retained 
in the labelled cells for at least 6 weeks post-transplantation, though with some 
degree of dilution due to mitosis [160]. Furthermore, the iron-labelled cells can also 
be magnetically recruited to the injured myocardium in vivo [161-163]. This suggests 
that iron-labelled cells can be mobilised to a target site with the aid of a magnet 
without affecting cell viability. Hence, this study also sought to apply MPIO for re-
isolating iron-labelled cells from a mixed cell population in in vitro culture.  
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PROBLEM STATEMENT AND OBJECTIVES 
 
 
Problem Statement: 
Heart contains endogenously-derived, c-kit expressing cardiac stem cells (CSCs) 
with regenerative capability. Mesenchymal stem cells (MSCs) had been shown to 
facilitate endogenous heart repair, but little is known about the synergy between 
endogenous cardiac stem cells and bone marrow-mesenchymal stem cells which can 
potentially be exploited during in vitro expansion prior to transplantation. 
Main objective 
To determine synergistic effects between cardiac stem cell and mesenchymal stem 
cells on CSC cardiomyocyte differentiation in vitro.  
The specific objectives of this study were: 
1. To isolate and characterise adult mouse cardiac stem cells and bone marrow 
derived mesenchymal stem cells from C57BL/6N mice. 
2. To determine whether cardiac stem cells can be re-isolated from 
mesenchymal stem cell co-culture by using micron-sized iron oxide particles. 
3. To identify the mode of synergistic interaction between cardiac stem cells and 
mesenchymal stem cells to exert superior cardiomyocyte differentiation in 
vitro. 
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2.0 METHODOLOGY 
 
2.1 Endogenous Cardiac Stem Cell Isolation, Culture and Expansion 
The protocol for CSC isolation was adapted from Smits et al. [133] with slight 
modifications. All procedures were conformed to USM animal ethical approval 
(USM/Animal Ethics Approval/ 2011/ (74) (357)). Briefly, CSCs were isolated from 
4-6 week-old C57BL/6N mice hearts (n=9). All mice were euthanised by carbon 
dioxide inhalation. The isolated hearts were removed and kept in Dulbecco’s 
Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F12) (Gibco®, Invitrogen 
Life Technologies Co., Carlsbad, CA, USA) supplemented with 10% Foetal Bovine 
Serum (Gibco®, Invitrogen Life Technologies Co., Carlsbad, CA, USA) and 1x 
Penicillin and Streptomycin (Gibco®, Invitrogen Life Technologies Co., Carlsbad, 
CA, USA). The hearts were washed twice with cold M-buffer (see appendix II) to 
remove blood cells. The isolated hearts were then transferred to a 100 mm cell 
culture-treated petri dish and minced into pieces with ~1mm
3 
in size, after which was 
followed by two washes with cold Dulbecco phosphate buffer saline (DPBS) 
(Gibco®, Invitrogen Life Technologies Co., Carlsbad, CA, USA).  The supernatant 
was removed and the heart tissues were allowed to settle at the bottom of conical 
tube before being treated with 1 mg/ml collagenase A (Roche Applied Science, US) 
for 2 hr at 37˚C in a waterbath. The tissues were vigorously shaken from time to time 
to facilitate digestion. After that, the digested heart tissues were filtered into a 50 ml 
conical tube through a 40 μm cell strainer (BD Biosciences Franklin Lakes, NJ, 
USA), followed by 5 washes with cold M-buffer (5 ml each) to separate 
cardiomyocytes and cardiac small cells. Then, the filtered cell suspension was 
centrifuged at 300 g for 5 min at room temperature and the procedure was repeated 
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once by re-suspending the cell pellet with 5 ml of cold M-buffer. After that, the cells 
were re-suspended in incubation medium (see appendix II)  and counted using a 
haemocytometer prior to sorting with  using EasySep® Mouse CD117 (c-kit) 
selection cocktail (STEMCELL Technologies, Vancouver, Canada) according to 
manufacturer’s protocols. Briefly, about 2 x 106 of the isolated cells were re-
suspended in 500 μl of incubation medium in a 5 ml polystyrene round bottom tube. 
Then, phycoerythrin (PE)-tagged CD 117 (c-kit) antibody (25 μl) was added and the 
cells were incubated for 15 min at room temperature. Then, EasySep® PE selection 
cocktail (STEMCELL Technologies, Vancouver, Canada) comprising monoclonal 
bispecific tetrametric antibody complex which targets PE and dextrose (35 μl), were 
added and incubated for 15 min at room temperature. This was then followed by 
incubation with magnetic dextran nanoparticles (25 μl) at room temperature for 10 
min. The mixture was topped up with incubation medium to 2.5 ml and the tube was 
put into a EasySep® magnet (STEMCELL Technologies, Vancouver, Canada) for 5 
min. Supernatant was discarded by inverting the tube and the magnet, and the 
labelled cells that retained in the tube were re-suspended in the incubation medium. 
The procedure was repeated up to four times. Positively selected c-kit
pos
 CSCs were 
re-suspended in fresh cardiac stem cell complete growth medium (CGM, see 
appendix II). The isolated CSCs were cultured in culture flasks coated with 1.5% 
(w/v) gelatin (Sigma-Aldrich, St Louis, MO, USA), at a density of ± 10,000/cm
2 
with 
CGM. For routine passaging, confluent CSCs were washed twice with pre-warmed 
DPBS, detached using 0.05% Trypsin-EDTA (Gibco®, Invitrogen Life Technologies 
Co., Carlsbad, CA, USA) at 37˚C and centrifuged at 330 g for 3 min. Supernatant 
was discarded and the cell pellet was re-suspended in fresh CGM.  
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2.2 CSC Colony Forming Unit and Cloning Assay 
As c-kit expressing CSCs were heterogeneous, this study employed two selection 
steps to obtain clonogenic, homogeneous population after magnetic sorting. First, the 
isolated CSCs were expanded up to three passages, prior to plating at ± 120 cells/cm
2
 
in CGM, and allowed to grow for 14 days in a 100 mm petri dish pre-coated with 
1.5% gelatin. Cell colonies with at least 20 cells and 1-8 mm in diameter were 
selected for subsequent clonogenic expansion. The cell colonies were selectively 
isolated by trypsinisation within a hydrophobic barrier drawn around the colony 
using ImmEdge hydrophobic barrier pen (Vector Laboratories, CA, USA). Secondly, 
the isolated colony forming cells were then seeded into a gelatin-coated 96-well plate 
at a density of one cell in every two wells. The plates were incubated for an hour 
inside a 5% CO2 incubator at 37˚C before checking under the microscope.  Wells that 
had only one cell were counted while wells with ≥ 2 or no cells will be excluded. 
CSCs were allowed to expand from single cells under standard culture conditions for 
2 weeks. Cloning efficiency was calculated using the formula as below. 
Cloning efficiency =  
Number of clones generated from single cell
Number of well with single cell at day 0
 X 100% 
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2.3 Murine Bone Marrow-derived Mesenchymal Stem Cell Isolation, 
Culture and Maintenance 
Bone marrow-derived mesenchymal stem cells (MSCs) were isolated from the femur 
and tibia bones of 4-6 weeks old C57BL/6N mice. Both the epiphysis end of the 
bones were cut open with sterile scissors and flushed through using 27-29G needles 
with incubation medium into a 50 ml conical tube until the bones became clear. The 
cells were centrifuged at 380 g for 5 min and re-suspended in fresh bone marrow 
mesenchymal stem cell growth medium (BMGM, see appendix II). Bone marrow 
cells were expanded up to passage 2 prior to sorting. All lineage-committed cells 
within the isolated MSCs were depleted using EasySep® Mouse Hematopoietic 
Progenitor Cell Enrichment Kit (STEMCELL Technologies, Vancouver, Canada) 
according to manufacturer’s protocols. Briefly, the bone marrow cells were re-
suspended in 500 μL incubation medium in a 5 ml polystyrene tube. Then, rat serum 
(25 μl) was added to the cells followed by 25 μl of EasySep® mouse hematopoietic 
progenitor cell enrichment cocktail. The cells were incubated on ice for 15 min. After 
that, EasySep® biotin selection cocktail (50 μl) was added and the cells were 
incubated on ice for 10 min. This was followed by incubation with 25 μl of magnetic 
nanoparticles on ice for 10 min. The solution was then brought up to 2.5 ml with 
incubation medium and left in the EasySep® magnet (STEMCELL Technologies, 
Vancouver, Canada) for 3 min. All labelled committed cells were retained in the 
magnet and lineage depleted MSCs were isolated from the supernatant. The cell was 
then centrifuged at 380 g for 5 min and maintained in fresh BMGM. Passage 10-11 
MSCs were used for all experiments described in this thesis.  
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2.4 Flow Cytometry 
To minimise the destruction of surface markers, cells were detached using TryPLE 
Express (Gibco®, Invitrogen Life Technologies Co., Carlsbad, CA, USA) and 
centrifuged at 380 g for 5 min. Then, the cells were re-suspended in incubation 
medium and cell number was determined using a haemocytometer. Approximately 2 
x 10
5
 cells were added into one 5 ml polystyrene tube. Cells were labelled with 
fluorescein isothiocyanate (FITC) and PE conjugated antibodies with dilutions as 
described in Table 2.1 at 4˚C in dark for 1 hour. The labelled cells were washed 
thrice with 500 μL DPBS at 300 g for 5 min prior to analysis with BD FACSCanto II 
flow cytometer (BD Biosciences Franklin Lakes, NJ, USA).  
Table 2.1: List of primary and secondary antibodies and its dilution factor for MSC 
characterisation 
Marker Catalogue 
Number 
Antibody Dilution Manufacturer 
CD 29-FITC 
Clone HMβ1-1 
130-102-503 1:10 Mitenyi Biotech 
CD 44-FITC 
Clone IM 7.8.1 
130-102-511 1:10 Mitenyi Biotech 
CD 105-PE 
Clone MJ7/18 
130-102-548 1:10 Mitenyi Biotech 
Sca-1-FITC 
Clone D7 
557405 1:50 BD 
CD 34-FITC 
Clone RAM 34 
560238 1:50 BD 
CD 45-FITC 
Clone 30F11 
130-102-491 1:10 Mitenyi Biotech 
CD 90.1-FITC 
Clone His51 
130-102-635 1:10 Mitenyi Biotech 
CD 90.2-FITC 
Clone 53-2.1 
553003 1:50 BD 
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2.5 Immunofluorescence Labelling 
Cells were re-suspended at a density of 1 x 10
5
 cells/ml and cytocentrifuged onto a 
glass slide using Cytospin™ 4 Cytocentrifuge (Thermo Scientific, Logan, UT, USA). 
Then, the cells were fixed with Shandon Cell-Fixx spray fixative (Thermo Scientific, 
Logan, UT, USA) and kept at room temperature. Prior to staining, the samples were 
treated with 95% ethanol to remove the wax for 15 min. For staining of intracellular 
proteins, samples were permeabilised using 0.1% Triton X-100 (Sigma-Aldrich, St 
Louis, MO, USA) for 10 min. Then, the samples were washed thrice with 0.1% 
Tween-20 (Sigma-Aldrich, St Louis, MO, USA) before blocking for 30 min in a 
humidifier chamber using blocking buffer with 10% donkey serum (Millipore, 
Billerica, MA, USA) to prevent unspecific binding. Samples were incubated with 
primary antibody overnight at 4˚C after diluted with 0.1% Tween-20 at specific ratio 
(Table 2.2). The samples were washed thrice with 0.1% PBS-Tween, followed by 
counter-labelling with secondary antibody diluted at 1:1000 in 0.1% PBS-Tween-20 
at 37˚C for 1 hr in the dark. After 3 washes with 0.1% PBS-Tween-20, the samples 
were counterstained with nuclei staining, 1 μg/ml of 4',6-diamidino-2-phenylindole 
(DAPI) for 14 min at room temperature. The slides were then mounted with 
VectaShield Mounting Medium (Vector Laboratories, CA, USA) with coverslips and 
sealed with clear nail polish around the edges for long term preservation. The 
samples were imaged with IX41 fluorescence microscope (Olympus, Japan) and the 
contrast was adjusted using Image J. The similar procedure applied to staining cells 
which were grown on Nunc Lab-Tek 8 well chamber slide (Thermo Scientific, 
Logan, UT, USA) after fixing with 4% paraformaldehyde (Sigma-Aldrich, St Louis, 
MO, USA) on ice for 20 min.  
 
 
24 
 
Table 2.2: List of antibodies used in this study and its dilution factor 
 
2.6 Cell Cycle Assay 
Cell samples (1 x 10
6
) were added and incubated with PI staining solution consisted 
of 250 μg/ml propidium iodide (PI) (Gibco®, Invitrogen Life Technologies Co., 
Carlsbad, CA, USA), 800 μg/ml RNase (Gibco®, Invitrogen Life Technologies Co., 
Carlsbad, CA, USA), and 0.8% Triton X-100 in DPBS in a 5 ml polystyrene tube. 
The cells were gently vortexed and incubated for 10 min at room temperature in the 
dark before they were examined using flow cytometer (BD FACSCanto II). All data 
were analysed using ModFitLT™ software. DNA QC particles (BD Biosciences 
Franklin Lakes, NJ, USA) consisted of chicken erythrocyte nuclei and calf 
thymocyte nuclei were used as the controls.  
Primary Antibody Manufacturer & 
Dilution (catalogue 
number) 
Secondary Antibody 
(Alexa Fluor® 488) 
CD 117 (H-300) 
Rabbit Polyclonal IgG 
Santa Cruz 
1:50 (sc-5535) 
donkey anti-rabbit 
1:1000 
Nkx 2.5 (H-114) 
Rabbit Polyclonal IgG 
Santa Cruz 
1:50 (sc-14033) 
donkey anti-rabbit 
1:1000 
GATA-4 (H-112) 
Rabbit Polyclonal IgG 
Santa Cruz 
1:50 (SC-9053) 
donkey anti-rabbit 
1:1000 
α-sacromeric actin  
Clone EA-53 
Rabbit anti-mouse 
Sigma-Aldrich 
1:200 (A 7811) 
donkey anti-rabbit 
1:1000 
Smooth muscle actinin  
Clone 1A4 
Mouse anti-mouse 
Sigma-Aldrich 
1:500 (A 2547) 
donkey anti-mouse 
1:1000 
Von Willebrand factor 
Rabbit anti-human 
Dako 
1:200 (A 0082) 
donkey anti rabbit 
1:1000 
Cardiac Troponin I (H-
170) 
Rabbit anti-mouse 
Santa Cruz 
1:50 (sc-15368) 
donkey anti-rabbit 
1:1000 
Myosin Heavy Chain 
Clone 3-48 
Mouse Monoclonal IgG 
Abcam 
1:200 (AB 15) 
donkey anti-mouse 
1:1000 
Anti-human nuclei 
Clone 235-1 
Mouse anti-human 
Millipore 
1:50 (MAB 1281) 
donkey anti-mouse 
1:1000 
